Chuzhou Qingyun Pharmaceutical Co., Ltd. ke a pharmaceutical manufacturing enterprise e khethehileng ho liphetho le nts'etsopele, tlhahiso le khoebo ea lisebelisoa tse sebetsang tsa meriana le liphetho tsa meriana. Khamphani e thehiloe ka la 28 Phupu, 2016, 'me e fumaneha ka leboea la Yanhua Avenue ho Yanhua Industrial Park, Dingyuan County, Chuzhou City, e nang le capital e ngolisitsoeng ea li-yuan tse 18 million.

Chuzhou Qingyun covers an area of 91 mu. The first phase has built one statin dedicated workshop, one 5,000-square-meter multi-functional workshop, one quality inspection office building, seven warehouses and power auxiliary facilities, etc. The company has over 180 reaction vessels with capacities ranging from 200 to 10,000 liters, covering reactions such as hydrogenation, oxidation, alkylation, and ultra-low temperature. The total reaction volume is 166,200 liters, and the wastewater treatment capacity reaches 500 cubic meters per day. Additionally, it is equipped with more than 50 sets of scientific research and testing instruments and equipment.

Ibhizinisi linezisebenzi eziningi ezikhethekile nezobuchwepheshe kanye nezinga eliphezulu lokutshalwa kwezimali ku-R&D, okwenza kube khona amandla angapheli okushayela intuthuko yokwakha. Kuze kube manje, sekuhlinzekwe ngama-patents angaphezu kwama-50, phakathi kwawo ama-30 asevele athole imvume (kuhlanganise nama-patents amathathu e-US).

Ibhizinisi lisebenze umkhiqizo ophathelene nezitho zenhliziyo kanye nemikhiqizo yesistimu yokusebenza emaphakathi. Ikhwalithi yomkhiqizo ihambisana nezindinganiso ze-USP, EP, JP kanye ne-CP, futhi imikhiqizo ithunyelwa ezweni elingaphezu kwamashumi amabili kuhlanganisa iJapane, iNingizimu Korea kanye neNdiya. Okwamanje, ibhizinisi lisebenza ngokuzikhandla ukuze libe "uphawu lwezokwelapha olukhulu emhlabeni lwezidakamizwa ezikhethekile nezithako", futhi sekuvele kwaba umphakeli ophakeme kumakampani amathathu aphezulu wezidakamizwa ezijwayelekile emhlabeni (i-TEVA evela e-Israel, i-SANDOZ evela eJalimane, kanye ne-DSM evela eNetherlands). Ikakhulukazi emikhakheni emibili yomkhiqizo ye-rosuvastatin calcium kanye ne-renozidine, ibhizinisi linemithombo yokuthengisa ezinzile kanye nezinsiza zamakhasimende aphezulu. Okwamanje, amaphrojekthi amasha ebhizinisi ahlanganisa i-kalidazine, i-pazoparib, kanye ne-ganirex acetate. Iphokophele ukuba ibe phezulu emhlabeni kulezi zinhlobo ezimbili ngo-2025.